Salute e Benessere

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

VANCOUVER, BC, Jan. 15, 2025 /PRNewswire/ -- As 2025 begins, the American Association for Cancer Research (AACR)recently published forecasts from experts showcasing transformative advances in cancer research, including cutting-edge AI technologies, novel targeted therapies, and innovative cancer vaccines. With over 50 oncology drug approvals in 2024, including the first tumor-infiltrating lymphocyte cell therapy, this year holds great promise for precision medicine and immunotherapy. Amid…
PR Newswire
15/01/2025

San Raffaele Hospital (Milan, Italy): new, promising results from the first…

The research has focused on two patients with incomplete spinal cord injuries that during 2023 had recovered their motor skills. This was possible thanks to the implantation of the spinal cord neurostimulator, a device already used in pain therapy. Researchers have applied targeted, high-frequency stimulations that, together with specific rehabilitation programs, have significantly improved muscular strength, walking ability and motor control of the patients. The applied stimulation protocol has…
PR Newswire
15/01/2025

IHS Passes Rigorous Audit for World-Wide Distribution of its Insignis™ Infusion…

Achieving MDR compliance at such an early stage highlights the dedication and expertise of the IHS team. This rigorous process required a meticulous adherence to MDR standards across all aspects of the device lifecycle, including conception, design, manufacturing, and post-market surveillance. Achieving MDR compliance at such an early stage highlights the dedication and expertise of the IHS team. This rigorous process required a meticulous adherence to MDR standards across all aspects of the...
PR Newswire
15/01/2025

Oxford-Harrington Rare Disease Centre Opens 2025 Call for Proposals

The OHC's 2025 Rare Disease Scholar Award seeks novel approaches to treat rare diseases, with a focus on neurological disorders, developmental and metabolic disorders, and rare cancers. Applications directed to other rare, genetic indications with a high unmet need are also of interest. Any therapeutic modality will be considered. Intellectual property rights are retained by the award recipient or their institution. The OHC's 2025 Rare Disease Scholar Award seeks novel approaches to treat…
PR Newswire
15/01/2025

Evaxion completes dosing in phase 2 trial with personalized cancer vaccine…

Trial remains on track for completion and data readout in the second half of 2025COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has now completed the dosing of all 16 patients in its phase 2 trial with the company's lead asset EVX-01. Designed with Evaxion's AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine being developed as a treatment...
Nasdaq GlobeNewswire
15/01/2025

BTL Unveils EXOMIND: A New Era in Mental Wellness

EXOMIND is FDA-cleared for depression in the United States, and also approved by Health Canada and CE-marked for treating depression, anxiety symptoms, obsessive-compulsive disorder and excessive eating disorders. EXOMIND is FDA-cleared for depression inthe United States, and also approved by Health Canada and CE-marked for treating depression, anxiety symptoms, obsessive-compulsive disorder and excessive eating disorders. "EXOMIND technology demonstrates our commitment to wellness by...
PR Newswire
15/01/2025

New Global Survey Seeks Insights on Climate and Health

Supported by a robust network of dissemination partners, this initiative will prioritize the voices of community health workers, nurses, physicians, researchers, health policymakers, and other health professionals in low- and middle-income countries (LMICs). Their input will offer local perspectives on the urgent and evolving health threats exacerbated by the climate crisis, such as heat-related illnesses, vector- and water-borne diseases, mental health challenges, and malnutrition. Supported...
PR Newswire
15/01/2025

Shortlist for 2024 ALCS Educational Writers' Award announced

This year's judges are School Library Services' librarian Cassie Hands, primary school teacher Kevin Cobane, and novelist and short story writer Ardashir Vakil. This year's judges are School Library Services' librarianCassie Hands, primary school teacherKevin Cobane, and novelist and short story writerArdashir Vakil. Kevin Cobanesaid: "It has been such a joy and a privilege to be a judge on the panel for this year's ALCS Educational Writers Award and after much deliberation the...
PR Newswire
15/01/2025

Recommendation by the Orion Nomination Committee on the proposals to be…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 15 JANUARY 2025 at 10.45 EET Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2025 Annual General Meeting The Nomination Committee of Orion Corporation has on 15 January 2025 given to the company's Board of Directors its recommendation on the proposal to the Annual General Meeting of 2025 concerning the composition of...
Nasdaq GlobeNewswire
15/01/2025

Mission Therapeutics announces publication in Nature Reviews Drug Discovery of…

Dr Paul Thompson, Chief Scientific Officer at Mission Therapeutics, said: "Fresh scientific approaches are needed if we as a society are to address the growing burden of neurodegenerative diseases, which are becoming ever more common as populations age. This timely review outlines the significant potential that enhancing mitophagy has in tackling a wide range of neurodegenerative diseases including Parkinson's, Alzheimer's, amyotrophic lateral sclerosis (ALS) and Huntington's."…
PR Newswire
15/01/2025

Piramal Pharma Limited Converts the Coal-Fired Steamer at its Digwal Facility to…

"The transition to biomass briquettes at our Digwal facility is a testament to our commitment to reducing our environmental footprint while driving innovation in sustainable manufacturing. As we align our goals with global climate action frameworks, we will continue to contribute to a more sustainable future for generations to come," said Nandini Piramal, Chairperson, Piramal Pharma Limited. "The transition to biomass briquettes at our Digwal facility is a testament to our…
PR Newswire
15/01/2025

2025 Sunhak Peace Prize: Honoring Global Leaders in Peace innovation

Hugh Evans, Co-founder and CEO of Global Citizen, has mobilized a remarkable $43.6 billionto combat poverty and advance global development. Through his advocacy, more than 1.3 billion lives worldwide have been positively impacted, with improved access to healthcare, education, and other essential services. Evans has redefined global activism, bridging grassroots movements with systemic policy changes to tackle inequality on a global scale. Hugh Evans , Co-founder and CEO ofGlobal Citizen,...
PR Newswire
15/01/2025

Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies…

Key Takeaways from the Non-Small Cell Lung Cancer Pipeline Report Key Takeaways from the Non-Small Cell Lung Cancer Pipeline Report Request a sample and discover the recent advances in NSCLC treatment drugs @Non-Small Cell Lung Cancer Pipeline Report The NSCLC pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage NSCLC drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining...
PR Newswire
14/01/2025

Evaxion announces completion of ADS ratio change

/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company's previously disclosed ratio change of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective.The ratio has changed from one (1) ADS representing ten (10) ordinary shares to a new ADS ratio of one (1) ADS representing fifty (50) ordinary shares (the...
Nasdaq GlobeNewswire
14/01/2025

Neurotechnology Boom: Brain-Computer Interface Market Forecast to Double by 2029

This report analyzes global Brain-Computer Interface (BCI) market trends, using 2023 as a baseline to forecast market value from 2024 to 2029. It includes revenue projections by component, technology, type, application, and region, while focusing on emerging technologies and the leading companies shaping the market during the forecast period. This report analyzes global Brain-Computer Interface (BCI) market trends, using 2023 as a baseline to forecast market value from 2024 to 2029. It…
PR Newswire
14/01/2025

SciBase announces final outcome of directed issue and rights issue

"I want to direct a big thank you to the existing and new shareholders that participated in the capital raise. SciBase will now receive capital to follow our commercialization strategy in the US aimed at skin cancer, and to invest further in product development within the business area skin barrier. I am looking forward to a 2025 with continued focus on improved diagnostics!", says Pia Renaudin, CEO Scibase. "I want to direct a big thank you to the existing and new shareholders…
PR Newswire
14/01/2025

Report on Carbios' liquidity contract with Natixis ODDO BHF

Shares concerned: Carbios (ISIN code: FR0011648716)Market concerned: Euronext Growth Paris Clermont-Ferrand (France), 14 January 2025 (6:00 pm CET).CARBIOS, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, reports today about the liquidity contract entrusted to Natixis ODDO BHF.As of December 31, 2024, the following assets appeared on the liquidity account: 22,546...
Nasdaq GlobeNewswire
14/01/2025

Clinical Informatics Market to Hit USD 563.18 Billion by 2030 with 16.0% CAGR |…

Browse in-depth TOC on "Clinical Informatics Market" Browse in-depth TOC on "Clinical Informatics Market" 400 - Tables 50 - Figures 300 - Pages Generative AI is reshaping healthcare by leveraging Artificial intelligence to enhance diagnostics, offering personalized risk assessments based on genetic and medical history. Many companies are actively pioneering the use of generative AI in healthcare, tackling diverse challenges and shaping the future of the industry. For…
PR Newswire
14/01/2025

icotec Announces FDA clearance for Spinal Infection Indication with BlackArmor®…

Furthermore, following the FDA decision, Centers for Medicare and Medicaid Services (CMS) approved BlackArmor® for New Technology Add-on Payment (NTAP), which is awarded when innovative medical technologies are determined to significantly improve the diagnosis or treatment of Medicare beneficiaries. Furthermore, following the FDA decision, Centers for Medicare and Medicaid Services (CMS) approved BlackArmor® for New Technology Add-on Payment (NTAP), which is awarded when innovative medical...
PR Newswire
14/01/2025

Conceivable Life Sciences Closes $18 Million Series A Financing to Advance…

ARTIS Ventures led the financing with participation from new and existing investors, raising over $39 million to dateFunds will support ongoing commercial pilot program in Mexico City and preparations for U.S. launch timed for early 2026A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Jan.14, 2025(GLOBE NEWSWIRE) -- Conceivable Life Sciences (Conceivable), a biotech company revolutionizing the future of fertility care...
Nasdaq GlobeNewswire
14/01/2025

BAIBYS™ Announces a Breakthrough in Fertility Treatment with a Newly CE Marked…

The BAIBYS™ system represents a breakthrough in male fertility treatment. By combining advanced AI algorithms with machine vision technology, ideal sperm cells are autonomously selected at high magnification, according to World Health Organization (WHO) criteria. The system not only selects, but also physically picks up and isolates the ideal cells effortlessly within minutes, addressing critical challenges in current sperm selection procedures. TheBAIBYS™ systemrepresents a breakthrough in...
PR Newswire
14/01/2025

Tyber Medical, Intech and Resolve Surgical Technologies combine to form a…

The combined entity will offer a unique mix of proprietary market-cleared technologies, and development and manufacturing scale, that will enable its OEM customers to achieve unmatched speed to market and improve the resiliency and effectiveness of their supply chain. At the time of the merger, the platform will be a leading contract supplier of systems for Spine, Trauma, Extremities, Sports Medicine and Enabling Technologies, with plans to expand its pioneering innovation-led model into…
PR Newswire
14/01/2025

FDA Clears Ariceum Therapeutics' 225Ac-Satoreotide Phase I/II Clinical Study in…

Germo Gericke, Chief Medical Officer at Ariceum Therapeutics, said: "This is an important milestone, not only for Ariceum but for the whole field of targeted radionuclide cancer treatments. 225Ac-SSO110 is the first somatostatin receptor 2 (SSTR2) antagonist labelled with Actinium-225 to undergo human trials, providing the optimum combination of a long half-life α particle emitter with a long tumour retention tracer. Based on encouraging clinical data with 177Lu-SSO110 and very promising…
PR Newswire
14/01/2025

Metabolon Appoints Michael Irwin as Vice President, Global Head of Sales

"We are thrilled to welcome Michael to the Metabolon leadership team during this pivotal time for the company. Michael comes to Metabolon from Olink, where he was head of global sales. As the life sciences industry moves towards a multiomic research approach, Michael's background in proteomics and genomics will help cement Metabolon's position as a leader in the emerging multiomics marketplace," said Rohan Hastie, Ph.D., President and CEO of Metabolon. "We are thrilled to welcome…
PR Newswire
14/01/2025
Altri  Comunicati